Session

Patient reported outcomes in IBD (Posters)

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

FATIGUE IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS FROM A PROSPECTIVE INCEPTION COHORT, THE IBSEN III STUDY
FATIGUE IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS FROM A PROSPECTIVE INCEPTION COHORT, THE IBSEN III STUDY

PSYCHOMETRIC VALIDATION AND INTERPRETATION OF A PATIENT-REPORTED OUTCOMES INSTRUMENT TO ASSESS BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
PSYCHOMETRIC VALIDATION AND INTERPRETATION OF A PATIENT-REPORTED OUTCOMES INSTRUMENT TO ASSESS BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER
REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

SURGERY IMPROVES SHORT AND LONG-TERM DISABILITY IN IBD: A 5-YEAR PROSPECTIVE ASSESSMENT OF THE SURGICAL PATIENT WITH IBD DISK
SURGERY IMPROVES SHORT AND LONG-TERM DISABILITY IN IBD: A 5-YEAR PROSPECTIVE ASSESSMENT OF THE SURGICAL PATIENT WITH IBD DISK

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH

DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH

Patient reported outcomes in IBD (Posters)  et al.

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

Patient reported outcomes in IBD (Posters)  et al.

SURGERY IMPROVES SHORT AND LONG-TERM DISABILITY IN IBD: A 5-YEAR PROSPECTIVE ASSESSMENT OF THE SURGICAL PATIENT WITH IBD DISK
SURGERY IMPROVES SHORT AND LONG-TERM DISABILITY IN IBD: A 5-YEAR PROSPECTIVE ASSESSMENT OF THE SURGICAL PATIENT WITH IBD DISK

Patient reported outcomes in IBD (Posters)  et al.

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Patient reported outcomes in IBD (Posters)  et al.

REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER
REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER

Patient reported outcomes in IBD (Posters)  et al.

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

Patient reported outcomes in IBD (Posters)  et al.

PSYCHOMETRIC VALIDATION AND INTERPRETATION OF A PATIENT-REPORTED OUTCOMES INSTRUMENT TO ASSESS BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
PSYCHOMETRIC VALIDATION AND INTERPRETATION OF A PATIENT-REPORTED OUTCOMES INSTRUMENT TO ASSESS BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Patient reported outcomes in IBD (Posters)  et al.

FATIGUE IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS FROM A PROSPECTIVE INCEPTION COHORT, THE IBSEN III STUDY
FATIGUE IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS FROM A PROSPECTIVE INCEPTION COHORT, THE IBSEN III STUDY

Patient reported outcomes in IBD (Posters)  et al.

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Patient reported outcomes in IBD (Posters)  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Patient reported outcomes in IBD (Posters)  et al.

Item 1 - 20 / 20
1